Evidence map›Paper›PMID 40856233›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Passivation-Engineered Zinc Peroxide Nanoparticles as Th1-Biased Adjuvant for Antitumor Immunity.

Jiangqi Luo, Yue Wang, Zan Dai, Yiru Shi, Weixi Wu, Jingjing Qu, Yuening Zhong, Jianqiao Xian, Chengzhong Yu, Yannan Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiangqi LuoSouth Australian immunoGENomics Cancer Institute, The University of Adelaide, Adelaide, South Australia, 5000, Australia.
Yue WangAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, 4072, Australia.
Zan DaiSchool of Clinical Medicine, The University of New South Wales, Sydney, New South Wales, 2052, Australia.
Yiru ShiSouth Australian immunoGENomics Cancer Institute, The University of Adelaide, Adelaide, South Australia, 5000, Australia.
Weixi WuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, 4072, Australia.
Jingjing QuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, 4072, Australia.
Yuening ZhongAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, 4072, Australia.
Jianqiao XianAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, 4072, Australia.
Chengzhong YuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, 4072, Australia.
Yannan YangSouth Australian immunoGENomics Cancer Institute, The University of Adelaide, Adelaide, South Australia, 5000, Australia.ORCID 0000-0001-6696-3879

Funding

Australia National Health and Medical Research Council 2010100Australian Research Council DP200102962Australian Research Council LP220200939University of QueenslandUniversity of Queensland animal ethic 2022/AE000646
6 · The paper itself

Abstract

The efficacy of cancer vaccines depends significantly on adjuvants that can stimulate robust Th1 immune responses. However, conventional inorganic adjuvants like Alum generally elicit Th2-biased immune response. Despite recent efforts in developing organic adjuvants to mimic bacterial or viral infections for generating Th1 immunity, excessive inflammation remains a major concern. Herein, a new class of Th1-biased adjuvant is reported via passivation engineering of zinc peroxide nanoparticles (p-ZPNs) for potentiating the immunogenicity of cancer vaccines. p-ZPNs show improved biocompatibility compared to unpassivated ZPNs due to retarded zinc ion release and hydrogen peroxide production, as well as efficient cellular uptake, endosome escape, dendritic cell maturation and antigen cross presentation. Mechanistic study indicates the intrinsic activity of p-ZPNs to activate toll-like receptors (TLR)-2, 4, and 6, triggering the TLR/Myeloid differentiation primary response 88 (MyD88)/Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) axis for producing proinflammatory cytokines and therefore a robust Th1 immunity. Biosafety evaluation has shown the importance of the passivation engineering of ZPNs in reducing safety risks. Furthermore, in a p-ZPNs-based autologous cancer vaccine model, potent immune response is demonstrated in the inhibition of B16F10 tumors in both prophylactic and therapeutic vaccination settings. These findings suggest the great potential of p-ZPN adjuvants for future Th1-biased vaccine development.

Indexed as

Adjuvants, ImmunologicNanoparticlesPeroxidesTh1 CellsAnimalsCancer VaccinesHumansMiceMice, Inbred C57BLToll-Like ReceptorsAdjuvants, ImmunologicCancer VaccinesPeroxidesToll-Like Receptorscancer vaccineimmunotherapynano‐adjuvantTh1 immunityzinc peroxide

Identifiers

PMID40856233
PMCPMC12548014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.